ABSTRACT
Introduction
The prevalence of atrial fibrillation (AF) and AF-related stroke events have been shown to increase with age.
1-6 Anticoagulation using warfarin is effective for the prevention of stroke or systemic embolic events. However, warfarin requires periodic blood monitoring and interacts with numerous drugs and food; thus, it is underutilized in elderly patients for fear of a higher risk of NOACs have been shown to be non-inferior to warfarin for the prevention of long-term stroke in patients with non-valvular AF. 8, 9 Moreover, they are associated with a significantly lower rate of intracranial hemorrhagic events and favorable survival benefits. 10 However, use of NOACs is dictated by the patient's renal function because a significant proportion of these drugs are excreted via the renal route. As renal function in elderly patients decreases, prescription of NOACs in the elderly, especially octogenarians, requires caution. 11 The present study aimed to analyze the efficacy (prevention of stroke or systemic embolism) and safety (risk of bleeding) of NOACs prescribed in a Korean octogenarian population.
Methods

Study Design and Subjects
The medical records of 158 patients aged ≥80 years and with non-valvular AF who started NOAC treatment for primary or secondary prevention of ischemic stroke or systemic embolism at the Asan Medical Center, Korea; between January, 2011 and September, 2014; were retrospectively reviewed. Non-valvular AF was defined as AF occurring in the absence of rheumatic mitral valve disease, a prosthetic heart valve, or mitral valve repair. 11 The baseline characteristics of the enrolled study patients are presented in 
Outcome Assessments
The efficacy outcome was the composite of ischemic stroke or systemic embolism. Stroke was defined as sudden onset of a focal neurological deficit lasting at least 24 hours. Systemic embolism was defined as acute vascular occlusion of an extremity or major organ as documented either at the time of autopsy or with angiography or vascular imaging.
The safety outcome was major bleeding. Major bleeding was defined as a decrease in hemoglobin levels ≥2 g/dL, transfusion of ≥2 units of packed red blood cells, symptomatic intracranial hemorrhage, and death from bleeding.
Two investigators reviewed the patients' medical records during the follow-up period and adjudicated all stroke, systemic embolism, and bleeding events that contributed to these prespecified outcomes. Event rates were presented as the number of events per 100 patient-years of follow-up.
Statistical Analysis
Statistical analysis was performed using the SPSS software package (Version 21, SPSS Inc., Chicago, IL), and data were expressed as the mean±SD (continuous variables) or as frequency (categorical variables).
Results
Renal Function in Octogenarians
The renal function as measured by eGFR showed a left-shift in the octogenarian population when compared with that measured of the younger population ( Figure 1 ). In the younger population, 
Efficacy of NOACs in the Octogenarian Population
No systemic embolic events were observed during the follow-up Values are expressed as the mean±SD, median (interquartile range) or number (percentage). Dose reduction refers to dabigatran 110 mg bid, dabigatran 10 or 15 mg qd. AF, atrial fibrillation; ASA, acetylsalicylic acid; CHF, congestive heart failure; CV, cardiovascular; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HT, hypertension; MI, myocardial infarction; NOACs, new oral anticoagulants; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; TIA, transient ischemic stroke. CHA2DS2-VASc is the cumulative score of congestive heart failure, hypertension, age (≥75 years or ≥65 years), diabetes, stroke, vascular disease, and sex (female). HAS-BLED is the cumulative score of hypertension, abnormal renal and liver function, stroke, bleeding, labile INRs, elderly (age >65 years), and drugs or alcohol. HAS-BLED 2.0±0.9 Figure 1 . Plot of serum creatinine (Cr) vs. estimated glomerular filtration rate (eGFR). The association of eGFR and creatinine levels from patients who were prescribed new oral anticoagulant is shown. Panel A depicts patients younger than 80 years, and B depicts those 80 years or older. The curves are shifted to the left in the older patients group. eGFRs were higher than 50 mL/min when serum creatinine levels were between 0.5 and 1.0 mL/min in patients younger than 80 years, while eGFRs were below 50 mL/min in approximately half (51%) of octogenarian patients. 
Discussion
The major findings of the present study are as follows: (1) NOACs were effective for the prevention of stroke or systemic embolism in octogenarian patients; (2) NOACs were discontinued in 18.9% of patients and the major cause of discontinuation was bleeding complications; and (3) .40/100 patient-years for warfarin in patients aged ≥75 years. 15, 16 Although there have as yet been no reports on the risk of bleeding from NOACs in this extreme age group, the risk of major bleeding (8.9/100 patient-years in our study) does not appear to be significantly different from that observed with the use of warfarin therapy (13.1/100 patient-years) and reported in previous studies of octogenarian patients. 7 In addition, a recent prospective observational Italian study reported that the rate of major bleeding was low (1.87/100 patient-years) in octogenarians on warfarin. 17 Thus, considering the reduced renal excretion capacity in an aged patient population and our own results regarding the risk of major bleedings in octogenarian patients, the currently recommended NOAC dosage may be higher than ideal. 
